Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425274 | 1.00 | HCAR2 (0.38) | HCAR2KEAP1NFE2L2CA2TSHR | |
| Ammonia Solution, Strong SCHEMBL29112117 | 0.92 | KEAP1 (0.33) | HCAR2KEAP1NFE2L2CA2 | |
| SCHEMBL1425276 | 0.89 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2CA2TSHR | |
| SCHEMBL8948865 | 0.89 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2CA2TSHR | |
| SCHEMBL1425277 | 0.89 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2CA2TSHR | |
| SCHEMBL28579726 | 0.87 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2TSHRTDP1 | |
| SCHEMBL28733317 | 0.84 | TSHR (0.33) | CA2TSHRTDP1 | |
| SCHEMBL8975780 | 0.77 | — | — | |
| SCHEMBL28258115 | 0.75 | TSHR (0.36) | CA2TSHR | |
| SCHEMBL27660393 | 0.75 | TSHR (0.36) | CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108101883-B | It is a kind of to be used to prevent drug of diabetic retinopathy and preparation method thereof | 佳木斯大学附属第医院 | 2018-11-13 | — | — | CN | disclosed |
| US-7148350-B2 | Compounds in the form of homodimeric or heterodimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterases-mediated diseases or dysfunction | CRISTALIA PROD.QUI.FARM. LTDA (BR) | 2006-12-12 | — | — | US | disclosed |
| EP-1315729-A4 | COMPOUNDS IN THE FORM OF HOMODIMERIC, HETERODIMERIC AND/OR HOMO AND HETEROMULTIMERIC PRO-DRUGS; PROCESS FOR OBTAINING THESE PRO-DRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASIS-MEDIATED DISEASES OR DYSFUNCTION | CRISTALIA PRODUTOS QUIMICOS E (BR) | 2004-07-07 | — | — | EP | disclosed |
| US-20040106629-A1 | Compouds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated deseases or dysfunction | PACHECO, OGARI (BR) | 2004-06-03 | — | — | US | disclosed |
| EP-1315729-A1 | COMPOUNDS IN THE FORM OF HOMODIMERIC, HETERODIMERIC AND/OR HOMO AND HETEROMULTIMERIC PRO-DRUGS; PROCESS FOR OBTAINING THESE PRO-DRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASIS-MEDIATED DISEASES OR DYSFUNCTION | Cristalia Produtos Quimicos e Farmaceuticos Ltda (BR) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002012241-A1 | COMPOUNDS IN THE FORM OF HOMODIMERIC, HETERODIMERIC AND/OR HOMO AND HETEROMULTIMERIC PRO-DRUGS; PROCESS FOR OBTAINING THESE PRO-DRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASIS-MEDIATED DISEASES OR DYSFUNCTION | Cristália Produtos Químicos e Farmacêuticos Ltda. (BR) | 2002-02-14 | — | — | WO | disclosed |
| US-5488146-A | SULFONATING MALEIC ANHYDRIDE WITH SULFUR TRIOXIDE; ADDING GLYCOLIC ACID; SALT FORMATION WITH ALKALINE EARTH OR ALKALI METAL HYDROXIDE; PRECIPITATING; ION EXCHANGING WITH SODIUM SALT | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1996-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106629-A1 | Compouds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated deseases or dysfunction | PEPD, PREP, PAPSS1 | HCAR2 916/4885KEAP1 4599/4885NFE2L2 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.